SLNP-based CDK4- targeted nanotherapy against glioblastoma

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
• Current treatments face challenges like drug resistance and toxicity.
• The retinoblastoma protein (pRB) pathway is crucial in glioblastoma development.

Purpose of the Study:

• To identify novel plant-derived compounds targeting the pRB pathway for glioblastoma treatment.
• To develop an efficient drug delivery system for enhanced glioblastoma therapy.

Main Methods:

• Screened 691 plant extracts for anti-cancer properties.
• Utilized molecular docking to identify potent compounds against pRB pathway proteins.
• Encapsulated the lead compound, silymarin, into solid lipid nanoparticles (SLNPs).
• Assessed cytotoxicity and anti-migratory effects on glioblastoma cell lines (U87, U251).

Main Results:

• Silymarin (Sil) was identified as a potent inhibitor of CDK4.
• SLNP-encapsulated silymarin (SLNP-Sil) demonstrated significant reduction in glioblastoma cell viability and migration.
• SLNP-Sil showed negligible toxicity to normal HEK-293 cells.

Conclusions:

• Silymarin and SLNP-Sil represent promising therapeutic strategies for glioblastoma.
• Further in vivo validation is warranted to confirm efficacy in preclinical models.